Extraneural hemangioblastoma of the kidney: the challenge for clinicopathological diagnosis

Yong Wu,1,2 Tao Wang,1,2 Pei-Pei Zhang,1,2 Xiaoqun Yang,1,2 Jian Wang,1,2 Chao-Fu Wang1,2

ABSTRACT

Background Hemangioblastoma is a benign cerebellar tumour which may occur as a sporadic entity or in association with von Hippel-Lindau (VHL) disease in approximately 25% of cases. Renal hemangioblastoma (RH) is an extremely rare and newly recognised tumour. Here, we describe five cases of RH, one discovered by CT in an accident and the other four detected during routine examinations.

Methods Five cases of renal hemangioblastoma retrieved from the Department of Pathology, Fudan University Shanghai Cancer Center were studied and the literatures were reviewed. Immunohistochemistry was used to differentiate and confirm this tumour.

Results Pathological examination following tumour resection revealed RH in all cases, the first patient was also diagnosed with renal cell carcinoma (RCC), suggesting the possibility of VHL syndrome, but PCR sequencing analysis of the VHL gene confirmed no mutation in any of the three exons, implying sporadic disease. Histologically, the tumours were circumscribed, composed of sheets of oval or polygonal cells and a prominent vascular network. Tumour cells had pleomorphic nuclei, but mitotic figures were rare. The diagnosis of hemangioblastoma was confirmed by immunohistochemistry.

Conclusions RH is very rare and is challenging to differentially diagnose. Distinguishing RCC and RH is difficult and each has a different prognosis, so differentiating between them is essential for avoiding over-diagnosis and unnecessary treatment.

INTRODUCTION

Hemangioblastoma is a benign tumour of uncertain histogenesis characterised by the presence of stromal cells and a rich vascular component. Most cases, which generally arise from the central nervous system (CNS), are sporadic, while approximately 25% are associated with von Hippel-Lindau (VHL) disease, an autosomal dominant disorder associated with germline mutations in the VHL tumour suppressor gene located on the short arm of chromosome 3.

Hemangioblastoma has also been reported outside the CNS, for example in the peripheral nerves, soft tissue, liver, lung, pancreas, kidney, retroperitoneum, urinary bladder, popliteal fossa and nasal skin. In this study, we describe five renal hemangioblastomas (RHs), all of which had features very similar to those of other malignancies such as renal cell carcinoma (RCC). We also describe the pathological and immunohistochemical features of this rare disease.

MATERIALS AND METHODS

All cases were sent to one of the authors for consultation. H&E-stained sections (4 mm thickness) were re-examined to evaluate the tumour’s histological features and immunohistochemistry was performed with an avidin-biotin-complex immunoperoxidase technique. Antibody details are given in Table 1. Appropriate positive and negative controls were used throughout.

Clinical demographics and follow-up data were obtained from medical records and the referring physicians. The institutional review board for human studies of Fudan University Shanghai Cancer Center approved this retrospective study. Patient records or information were anonymised and de-identified prior to analysis. Written informed consent was provided by participants or their next-of-kin for their clinical records to be used in this study.

RESULTS

Clinical characteristics of five cases

Case 1

A 30-year-old man was admitted to the hospital for examination after an accident and a CT scan revealed a mass with a different density within a right kidney lesion. The malignancy was subsequently imaged by MRI. Surgical resection of the tumour revealed a collision tumour comprising RCC and extraneural hemangioblastoma, among which RCC accounts for less than 5% of the total tumour volume. The mass involved the renal cortex and medulla and measured 3.2×2.5×1.4 cm. VHL disease was initially suspected. However, PCR sequencing analysis of the VHL gene confirmed no mutation in any of the three exons, suggesting sporadic disease. The patient died before the next follow-up.

Case 2

A CT scan during a routine examination revealed that a 57-year-old woman had a mass in her right kidney. A radical nephrectomy was performed as a malignant tumour was suspected. H&E slides confirmed the diagnosis of RCC. No surgery or chemotherapy was carried out. The patient is currently alive with no evidence of recurrent tumour or the development of other tumours.

Case 3

The patient was a 48-year-old man with no hereditary diseases. When he visited the hospital for evaluation of organ function, abdominal sonography revealed a tumour mass in the right kidney. A CT scan confirmed a 2.3 cm mass with heterogeneous density in the lower portion of the right kidney. As RCC was suspected, the
patient underwent a right radical nephrectomy. There was no evidence of tumour recurrence 42 months after the surgery. Follow-up magnetic resonance brain imaging did not reveal any new tumours.

Case 4
A 25-year-old man was confirmed to have a left renal tumour during a routine examination, and was admitted to hospital for urological examination. The patient was asymptomatic with a normal appetite, no abdominal pain, no weight changes, and no family history of renal disease. CT imaging revealed a 3.6 cm well-defined, round, heterogeneously enhancing mass in the left kidney. Nephrectomy was performed and a 4.1 cm encapsulated tumour removed. Follow-up at 27 months confirmed no tumour recurrence or metastasis.

Table 1  Panel of antibodies used in this study

| Antigen | Clone | Dilution | Source                          |
|---------|-------|----------|---------------------------------|
| S100    | Polyclonal | 1:2000  | Dako, Carpinteria, California, USA |
| Vimentin| V9    | 1:200   | Dako                            |
| EMA     | E29   | 1:500   | Dako                            |
| HMB-45  | HMB-45| 1:20    | Dako                            |
| CD34    | QBEnd10| 1:500   | BioGenex, San Ramon, California, USA |
| CD31    | JC70A | 1:50    | Dako                            |
| PAX8    | Polyclonal | 1:800  | Dako                            |
| AE1/AE3 | AE1/AE3| 1:100   | Dako                            |
| Inhibin | R1    | 1:50    | Dako                            |
| NSE     | BBS/NOVI-H14| 1:200  | Dako                            |
| CK7     | OV-TL 12/30 | 1:50  | Dako                            |
| CK8     | CAM5.2 | 1:10    | Becton Dickinson, San Jose, California, USA |
| CK      | AE1/AE3| 1:100   | Dako                            |

NSE, neuron-specific enolase.

Microscopic features
Microscopically, most tumours were well circumscribed and well demarcated from the surrounding renal parenchyma; only one tumour had areas of poorly marginated growth. The RHs all consisted of sheets of oval or polygonal cells traversed by a prominent, arborising vascular network (figure 1A, B). The tumours also included small microvacuolated cells with palely eosinophilic or clear cytoplasm (figure 1C, D). These microvacuolated cells often mimicked RCC. All tumours had a complex capillary network and blood vessels, which were thin-walled and lined with flat to plump endothelial cells, often had ectasia or pericytomatic configurations (figure 2). Case 1 had a focally marked nucleus.

Figure 1  Histological features. (A) Most tumours were solid and were traversed by arborising thin-walled blood vessels. (B) Tumours were composed of plump spindle cells with palely eosinophilic cytoplasm. (C) The microvacuolated cells often mimicked lipoblasts or renal cell carcinoma and were mildly atypical. (D) Abundant anastomosing thin blood vessels surrounding bland-appearing stromal cells. Under a high-power field, scattered tumour cells have highly pleomorphic nuclei.

Figure 2  Blood vessels often had ectasia or pericytomatos configurations.

Case 5
A previously healthy 36-year-old woman presented with a tumour on the left kidney during a routine examination. The tumour was an unencapsulated but sharply circumscribed nodule. Clear cell RCC (CCRCC) was diagnosed. Immunohistochemistry of a tissue sample suggested a diagnosis of RH. The patient was alive 3 months later.
pleomorphism; nuclear pleomorphism of the other cases were generally difficult to detect. There were a very few mitotic figures in one case and none at all in the other cases. In all cases, there were minimal areas of stromal hyalinisation. Necrosis or lympho-vascular invasion was not identified in any case.

Immunohistochemical findings
Most cases had similar immunohistochemical profiles. Tumour cells expressed inhibin (3/5) and vimentin (3/5) in 60% of cases (figure 3A, B). Neuron-specific enolase (NSE) and S100 protein were expressed in all cases (figure 4A, B). EMA was focally positive in stromal cells in half of the cases (figure 5). Four of the tumours were negative for CK, CK7, CK8, PAX8, AE1/AE3 and HMB45 (figure 6A–F). CD31 or CD34 stains highlighted the capillary network but not tumour cells (figure 7). Interestingly, one case had markers for both hemangioblastoma and CCRCC, suggesting the possibility of VHL syndrome. Immunohistochemistry data are summarised in table 2.

DISCUSSION
Hemangioblastoma is a benign tumour of uncertain histogenesis that generally occurs in a relatively restricted area of the CNS. Extraneural cases are seldom seen and usually accompany VHL disease. This report describing two female and three male patients (median age 39.2 years; range 25–57 years) with RH adds to the total number of published cases (table 3). In contrast to CNS hemangioblastoma which is predominantly found in males, renal tumours affect both male and female patients. CNS hemangioblastoma is found predominantly in the third to the fifth decades of life. However, patients in our series were younger than those in previous reports, but this may not be significant as our sample size was small.

VHL disease is an autosomal dominant hereditary disorder characterised by retinal and CNS hemangioblastomas, pheochromocytoma and CCRCC. Mutations in the VHL gene lead to the development of several benign or malignant tumours, and cysts in many organ systems. The VHL gene which is located on chromosome 3p25, encodes for a 213 amino acid tumour suppressor protein that plays a key role in the regulation of the hypoxia response pathway. Aberrations in VHL function, either through mutation or other mechanisms, lead to the accumulation of hypoxia-inducible factor, which then transcriptionally upregulates a sequence of hypoxia responsive genes, including epidermal growth factor, vascular endothelial growth factor, platelet-derived growth factor and other pro-angiogenic factors, resulting in tumour formation. It is currently recommended that all patients with CNS hemangioblastoma undergo testing for VHL germline mutations. According to the WHO Blue Book, the clinical diagnosis of VHL disease is based on the presence of hemangioblastoma in the CNS or retina, the presence of one of the
typical VHL-associated tumours, or a previous family history. In the present study, one case which expressed markers of hemangioblastoma and CCRCC was subjected to Sanger DNA sequencing. Each exon was identified and confirmed by both forward and reverse directional analyses but no mutation was detected. None of the other patients met any of these criteria, and are considered to have sporadic disease.

The tumours in these five cases were morphologically similar to lesions arising in the CNS, which are also composed of sheets of oval or polygonal cells with palely eosinophilic and

| Table 2 | Results of immunohistochemical staining in renal hemangioblastoma (RH) |
|---------|---------------------------------------------------------------------|
| Case 1  | RH  | RCC | Case 2 | Case 3 | Case 4 | Case 5 |
|---------|-----|-----|--------|--------|--------|--------|
| Vimentin | +   | +   | +      | −      | −      | +      |
| S100    | +   | −   | +      | +      | +      | +      |
| Inhibin | +   | −   | +      | −      | −      | +      |
| NSE     | +   | +/− | N/A    | +      | +      | +      |
| EMA     | +   | +   | −      | −      | N/A    | +      |
| CK7     | −   | +   | −      | −      | −      | −      |
| CK8     | −   | +   | −      | −      | −      | −      |
| CK      | N/A | N/A | −      | −      | N/A    | −      |
| CD10    | −   | +   | −      | −      | −      | +      |
| AE1/AE3 | −   | +   | −      | −      | −      | −      |
| HMB45   | N/A | N/A | N/A    | −      | −      | −      |
| CD31    | N/A | N/A | N/A    | +      | N/A    | N/A    |
| CD34    | +   | −   | +      | +      | +      | +      |
| PAX8    | −   | +   | −      | −      | −      | −      |

NA, stain not performed; NSE, neuron-specific enolase; RCC, renal cell carcinoma; +, positive; −, negative; +/−, variable.
clear microvacuolated cytoplasm, separated by a delicate capillary network, and usually with interspersed larger thin-walled and thick-walled blood vessels.

Compared with CNS hemangioblastoma, the results of immunohistochemical staining reported by many authors do not suggest a specific line of differentiation for RH tumours.16 24–27 Markers currently used for these lesions include epithelial (cytokeratins), muscle (MSA, desmin, calponin), neural (S100 protein, neuron specific enolase) and other generic mesenchymal markers (vimentin); vimentin, S100 protein, NSE and inhibin are reported to express constantly in this tumour.

In the current study, S100 and NSE appeared to be the most sensitive markers and were expressed in all cases, as was inhibin. Vimentin expression was observed in 60% of cases. Of note, expression of inhibin was less in our cases than reported in the literature; sample limitations may explain this discrepancy. The fact that vimentin is strongly expressed in these tumours has led investigators to suggest they have an undifferentiated mesenchymal origin.4 Expression of GLUT1 in CNS hemangioblastoma has been reported to be helpful for differential diagnosis with metastatic RCC, as is the strong endothelial staining observed with most hemangioblastomas, unlike RCC, which does not show such a staining pattern.26 However, this finding is controversial, as some authors29 doubt the low specificity and tendency for high background staining. Recently, expression of brachyury has been described in cerebellar hemangioblastoma tumour cells.30 31 Tirabosco’s group30 reported nuclear expression of brachyury in stromal cells in all 14 CNS cases they examined. However, Doyle and Fletcher29 reported that brachyury was not expressed in extraneural tumours in their series.

RH is frequently misdiagnosed as RCC, and is likely to be under-recognised as it mimics many tumour types morphologically and is usually not considered in a differential diagnosis.4 Correctly diagnosing RH is challenging and important because sporadic RH does not require further treatment and the prognosis is much better than that of malignant RCC.14 15 The presence of pericytomatous growth patterns and intracytoplasmic lipid vacuoles strongly suggests hemangioblastoma,13 13 although both tumour types have similar morphological features, such as clear cytoplasm and a vascular network.14 Immunohistochemistry is useful for differentiating morphologically similar neoplasms, such as renal cell carcinoma.

### Take home messages

- Extraneural renal hemangioblastoma (RH) is a rare, newly recognised tumour with morphological features similar to its cerebellar counterpart.
- This report describes the morphological features and immunohistochemical characteristics of five cases of RH and summarises the findings.
- RH is frequently misdiagnosed, so immunohistochemistry is essential for differentiating RH from morphologically similar neoplasms, such as renal cell carcinoma.

### Handling editor
Check Soon Lee

### Contributors
YW and TW collected and analyse the data. XY help to analyse the data and examine the H&E slides. YW and P-PZ are responsible for writing the paper. C-FW and JW are responsible for the entire experiment and correcting the manuscript.

### Competing interests
None declared.

### Ethics approval
The institutional review board for human studies of Fudan University Shanghai Cancer Center approved this retrospective study.

### Provenance and peer review
Not commissioned; externally peer reviewed.

### Open Access
This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.

### REFERENCES

1. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97–109.
2. Latif F, Tony K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993;260:1317–20.

### Table 3 Reported cases of renal hemangioblastoma

| References | Age | Gender | Presence of VHL | Outcome |
|------------|-----|--------|-----------------|---------|
| Nonaka et al10 | 71 | F | Not stated | No recurrence 9 years after nephrectomy |
| Ip et al13 | 58 | M | No | No recurrence 2 years after nephrectomy |
| Ip et al13 | 55 | F | No | Well after nephrectomy |
| Wang et al15 | 29 | M | No | No recurrence 20 months after nephrectomy |
| Verine et al30 | 64 | M | No | No recurrence 1 year after nephrectomy |
| Wang et al14 | 61 | M | No | No recurrence 1 year after nephrectomy |
| Liu et al86 | 36 | F | Suggestive of VHL | Died after nephrectomy |
| Current case 1 | 30 | M | No | No recurrence 3.5 years after nephrectomy |
| Current case 2 | 48 | M | No | No recurrence 27 months after nephrectomy |
| Current case 3 | 25 | M | No | Well after nephrectomy |
| Current case 4 | 36 | F | No | No recurrence 5 months after nephrectomy |

VHL, von Hippel-Lindau disease.
19 Cowey CL, Rathmell WK. VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy. *Cancer Res* 1998;58:941–946.
20 Gnaiger E, Knopp C, Wieland F, et al. Mitochondrial DNA mutations in patients with familial leiomyomatosis. *Hum Genet* 2000;107:240–244.
21 Lee Y, Dong SM, Park WS, et al. Loss of heterozygosity and somatic mutations of the VHL tumor suppressor gene in sporadic cerebellar hemangioblastomas. *Cancer Res* 1998;58:504–8.

22 Iliopoulos O, Levy AP, Jiang C, et al. Negative regulation of hypoxia-inducible genes by the von Hippel Lindau protein. *Proc Natl Acad Sci USA* 1999;96:10595–9.
23 Wiesner MS, Munchenerhagen PM, Berger I, et al. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1 alpha in clear cell renal carcinomas. *Cancer Res* 2001;61:5215–22.
24 Frank TS, Trojanowskij JO, Roberts SA, et al. A detailed immunohistochemical analysis of cerebellar hemangioblastoma: an undifferentiated mesenchymal tumor. *Mod Pathol* 1998;2:638–51.
25 Ishizawa K, Komori T, Hirose T. Stromal cells in hemangioblastoma: neuroectodermal differentiation and morphological similarities to ependymoma. *Pathol Res Pract* 2005;55:377–85.
26 Hoang MP, Amirkhan RH. Inhibin alpha distinguishes hemangioblastoma from clear cell renal cell carcinoma. *Am J Surg Pathol* 2003;27:1152–6.
27 Weinbreck N, Marie B, Bressenot A, et al. Immunohistochemical markers to distinguish between hemangioblastoma and metastatic clear cell renal cell carcinoma in the brain: utility of aquaporin1 combined with cytokeratin AE1/AE3 immunostaining. *Am J Surg Pathol* 2008;32:1051–9.
28 North PE, Mizerek AJ, Mihm MC Jr, et al. GLUT1 immunoreaction patterns reliably distinguish hemangioblastoma from metastatic renal cell carcinoma. *Clin Neuropathol* 2000;19:131–7.
29 Doyle LA, Fletcher CD. Peripheral hemangioblastoma: clinicopathological characterization in a series of 22 cases. *Am J Surg Pathol* 2014;38:119–27.
30 Tirabosco R, Mangham DC, Rosenberg AE, et al. Brachyury expression in extrarenal soft tissue tumours: a marker that distinguishes chondroma from mixed tumor/myoepithelioma/parachordoma in soft tissue. *Am J Surg Pathol* 2008;32:572–80.
31 Barresi V, Vitarelli E, Branca G, et al. Expression of brachyury in hemangioblastoma potential use in differential diagnosis. *Am J Surg Pathol* 2012;36:1052–7.
32 Nonaka D, Rodriguez J, Rosai J. Extraneuronal hemangioblastoma: a report of 5 cases. *Am J Surg Pathol* 2007;31:1545–51.
33 Verine J, Sandid W, Miquel C, et al. Sporadic hemangioblastoma of the kidney: an underrecognized pseudomalignant tumor? *Am J Surg Pathol* 2011;35:623–4.
34 Amin MB, McKenney J, Tickoo S, et al. Diagnostic pathology: genitourinary. Altona, MB, Canada: Aminsys, 2010.
35 Lapinska JE, Chen L, Zhou M. Distinguishing clear cell renal cell carcinoma, retropertitoneal paranglioma, and adrenal cortical lesions on limited biopsy material: utility of immunohistochemical markers. *Appl Immunohistochem Mol Morphol* 2010;18:414–21.
36 Liu Y, Qiu XS, Wang EH. Sporadic hemangioblastoma of the kidney: a rare renal tumor. *Diagn Pathol* 2012;7:49.